在炎症性肠病中,N4BP3激活TLR4-NF-κB通路,通过促进与K48相关的IκBα泛
Wang Jiang1, Jie Yin1, Min Han2
1Department of Digestive Diseases, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, 410000, People's Republic of China.
Journal of inflammation research
|June 9, 2025
概括
N4BP3基因表达被LPS上调,通过激活NF-κB通路来促进炎症性肠病 (IBD). 针对N4BP3可能为IBD提供新的治疗策略.
科学领域:
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- N4BP3是一种与无处不在相关的基因,涉及神经和瘤疾病.
- 以前的研究将N4BP3与通过NOD2信号通路增强的炎症反应联系起来.
- 通过TLR4信号通路在炎症性肠病 (IBD) 中N4BP3的作用仍然未被探索.
研究的目的:
- 通过TLR4信号通路调查N4BP3在调节炎性肠病 (IBD) 中的作用.
- 阐明N4BP3影响IBD病变的潜在分子机制.
主要方法:
- 利用了THP-1/Caco-2细胞系与N4BP3过度表达或淘汰,用脂多糖 (LPS) 刺激激活TLR4通路.
- 已建立的德克斯硫酸 (DSS) 诱导的大肠炎小鼠模型和使用腺相关病毒 (AAV) 的N4BP3敲击式小鼠模型.
- 通过mRNA和蛋白质水平分析了炎症标志物表达 (TNF-α,IL-1β,IL-6,IL-8) 和NF-κB通路组件 (-NF-κB p65,IκBα),并评估了K48相关的无处不在.
主要成果:
- 在THP-1/Caco-2细胞中,LPS刺激显著上调N4BP3表达.
- 过度表达N4BP3放大了LPS诱导的炎症性细胞因子产生和NF-κB激活,而N4BP3的淘汰减弱了这些效应.
- 在体内,在DSS诱导的大肠炎小鼠中,N4BP3的敲除降低了-NF-κB p65和增加了IκBα表达,表明NF-κB信号被抑制.
- 发现N4BP3与IκBα相互作用,促进其与K48相关的无处不在.
结论:
- LPS上调N4BP3,从而增强IκBα的无处不在,导致NF-κB通路的激活和IBD的恶化.
- 在TLR4驱动的与IBD相关的炎症中,N4BP3成为关键的调解者.
- N4BP3代表了新的IBD治疗的潜在治疗标.
相关概念视频
NF-κB-dependent Signaling Pathway
7.3K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Inflammatory Bowel Disease I: Ulcerative Colitis
148
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
148
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K


